Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (2)

Trial Status

Withdrawn1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06483048Phase 1Recruiting

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

NCT06393751Phase 1Withdrawn

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Showing all 2 trials

Research Network

Activity Timeline